Navigation Links
TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimer's Disease Research, His Third Endowed Chair
Date:7/10/2012

PHILADELPHIA, July 10, 2012 /PRNewswire/ -- TREVENTIS Corporation announced today that the Company's scientific founder, Donald F. Weaver, MD, PhD, was named as the Sobey Chair in Alzheimer's disease research at Dalhousie University in Halifax, Nova Scotia, Canada.  This is the third endowed chair to be held by Dr. Weaver at Dalhousie.  This chair has been established as the result of a $2 million donation to the Dalhousie Medical Research Foundation (DMRF) from the Sobey Foundation.  It will fund the DMRF Irene MacDonald Sobey Endowed Chair in Curative Approaches to Alzheimer's Disease.  The Sobey Foundation is funded by the Sobey family, who operate many diverse companies throughout Canada including chain grocery and drug stores.

Dr. Weaver, a pioneer in the field of computer-aided drug development, is on the trail of an Alzheimer cure.  Dr. Weaver's group uses state-of-the-art computer-aided modeling to develop drugs to prevent and/or slow the progression of Alzheimer's disease.  When certain proteins in the brain aggregate into clumps or tangles, that process is toxic to the brain, killing brain cells and leading to the symptoms of Alzheimer's dementia.  Using computer models, Dr. Weaver is developing drugs that bind to multiple misfolding proteins in the brain, preventing them from aggregating and, thus, halting the brain damage associated with Alzheimer's disease.

The Sobey Chair in Alzheimer's will provide stable annual funding to assist Dr. Weaver and his team in their continued development of lead compounds as potential curative agents for the treatment of Alzheimer's disease.  Dr. Weaver assigns these compounds for commercialization to TREVENTIS Corporation, a company that he helped found.

"We congratulate Don on this most prestigious appointment that serves to support his over- 20-year's work to discover a cure for dementias such as Alzheimer's," said Bill McIntosh, Chairman and CEO of TREVENTIS.  "The Company is pleased to work toward the ultimate commercialization of his discoveries."

About TREVENTIS Corporation 

TREVENTIS is headquartered in Southeastern Pennsylvania and has research operations in Halifax, Nova Scotia, Canada.  The Company is focused on the discovery and early stage development of disease-modifying small molecule drugs for a variety of dementias including Alzheimer's.  In addition to its therapeutic programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis and monitoring of treatment effects in Alzheimer's disease.  

Contact: L. William McIntosh

TREVENTIS, Chairman and CEO

Phone: 610-488-6081

wmcintosh.treventis@gmail.com


'/>"/>
SOURCE TREVENTIS Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Neogen Corporation Announces 2nd Quarter Results Conference Call
5. Luminex Corporation to Present at JP Morgan Healthcare Conference
6. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
7. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
8. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
9. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
10. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
11. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Village, CA (PRWEB) , ... August 17, 2017 ... ... technology for cancer research and personalized medicine, today announced the launch of a ... Kansas City, Missouri. The study’s goal is to evaluate the potential for early ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics Inc ... $2M in funding from an impressive group of investors, including Rev1 Ventures, Maumee ... With this investment, 3Bar is broadening availability of its groundbreaking offering that uses ...
(Date:8/15/2017)... Charlotte, NC (PRWEB) , ... August 15, 2017 , ... ... in 2017, celebrating 10 years of successes helping medical technology companies and inventors develop ... company to a renowned full-service national engineering firm with a portfolio of clients in ...
(Date:8/15/2017)... , ... August 15, 2017 , ... The Conference ... on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The ... 7-9, 2018, at The Roosevelt Hotel in New York City. , “With our experience ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):